Status:
UNKNOWN
Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
Lead Sponsor:
Yooyoung Pharmaceutical Co., Ltd.
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
Phase 3 study to assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
Detailed Description
Phase 3 study to assess the Efficacy and Safety of YYC405-T when added to Metformin and Dapagliflozin combination therapy in patients with type 2 diabetes mellitus who have inadequate glycemic control
Eligibility Criteria
Inclusion
- Patient who contsent to participate in this tiral by written informed consent form
- A man or woman over 20 years old
- Type 2 Diabetes patients
Exclusion
- Patients with severe renal impairment, end-stage renal disease or on dialysis
- Type 1 diabetes patients
- Patients with a history of acute or chronic target acidosis, including lactic acidosis and diabetic ketoacidosis
Key Trial Info
Start Date :
July 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 26 2023
Estimated Enrollment :
256 Patients enrolled
Trial Details
Trial ID
NCT05226897
Start Date
July 12 2021
End Date
June 26 2023
Last Update
June 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Catholic University of Korea(Bucheon St. Mary's Hospital)
Bucheon-si, South Korea